- 학회지
권호별 검색
- 현재 페이지 경로
-
- HOME
- 학회지
- 학회지
- 권호별 검색
| Review | |||||
| Dementia and Neurocognitive Disorders 2020: 19: 1: 1-18 | |||||
| Alzheimer's Disease Diagnosis Using Misfolding Proteins in Blood | |||||
|---|---|---|---|---|---|
| HeeYang Lee , 1,2,3 Daniella Ugay , 1,2,3,4 Seungpyo Hong , 2,5,6 YoungSoo Kim 1 | |||||
| Integrated Science Engineering Division, Yonsei University, Incheon, Korea 2 Department of Pharmacy, Yonsei University, Incheon, Korea 3 Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Korea 4 Underwood Division, Yonsei University, Incheon, Korea 5 Yonsei Frontier Lab, Yonsei University, Incheon, Korea 6 Pharmaceutical Sciences Division, School of Pharmacy and Carbone Cancer Center, School of Medicine & Public Health, University of Wisconsin, Madison, WI, USA | |||||
| Alzheimer's Disease Diagnosis Using Misfolding Proteins in Blood | |||||
| HeeYang Lee , 1,2,3 Daniella Ugay , 1,2,3,4 Seungpyo Hong , 2,5,6 YoungSoo Kim 1 | |||||
| Integrated Science Engineering Division, Yonsei University, Incheon, Korea 2 Department of Pharmacy, Yonsei University, Incheon, Korea 3 Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Korea 4 Underwood Division, Yonsei University, Incheon, Korea 5 Yonsei Frontier Lab, Yonsei University, Incheon, Korea 6 Pharmaceutical Sciences Division, School of Pharmacy and Carbone Cancer Center, School of Medicine & Public Health, University of Wisconsin, Madison, WI, USA | |||||
| Alzheimer's disease (AD) is pathologically characterized by a long progressive phase of neuronal changes, including accumulation of extracellular amyloid-β (Aβ) and intracellular neurofibrillary tangles, before the onset of observable symptoms. Many efforts have been made to develop a blood-based diagnostic method for AD by incorporating Aβ and tau as plasma biomarkers. As blood tests have the advantages of being highly accessible and low cost, clinical implementation of AD blood tests would provide preventative screening to presymptomatic individuals, facilitating early identification of AD patients and, thus, treatment development in clinical research. However, the low concentration of AD biomarkers in the plasma has posed difficulties for accurate detection, hindering the development of a reliable blood test. In this review, we introduce three AD blood test technologies emerging in South Korea, which have distinctive methods of heightening detection sensitivity of specific plasma biomarkers. We discuss in detail the multimer detection system, the self-standard analysis of Aβ biomarkers quantified by interdigitated microelectrodes, and a biomarker ratio analysis comprising Aβ and tau. |
|||||
| Key Words: Alzheimer's Disease; Amyloid-beta Peptides; Biomarkers; Diagnostic Techniques and Procedures; Plasma; tau Proteins | |||||
- Sponsor
-
- Tel : +82-2-587-7462
- Fax : +82-2-587-7482
- e-mail : secretkda@thedementia.co.kr
- 사업자등록번호 : 214-82-63838
- 상호 : 대한치매학회
- 대표자명 : 최성혜 이사장
Copyright © The Korean Dementia Association, All rights reserved